How biologics manufacturing differs from small-molecule manufacturing, from upstream processing through characterization complexity.
This course covers how biopharmaceutical manufacturing differs fundamentally from small-molecule drug manufacturing, upstream and downstream processing basics including cell culture, harvest and purification, why biologics characterization is more complex than small-molecule analytical testing, and cold chain and stability considerations specific to biologic products.
A biologic is defined in large part by the process used to make it, unlike a small molecule, which means a manufacturing change can alter the product itself in ways small-molecule intuition doesn't anticipate. That single difference shapes nearly everything else about how biologics are controlled.
Completion certificate, PDF slide download, and access to the complete GMP course library from day one.
Start this course →